Balixafortide TFA (POL6326 TFA) 是一种有效的，选择性的，耐受性好的肽类 CXCR4 拮抗剂，其 IC50 小于 10 nM。Balixafortide TFA 对 CXCR4 的选择性比包括 CXCR7 在内的许多受体高出 1000 倍。Balixafortide TFA 以 IC50< 10 nM 阻断 β-arrestin 募集和钙通量。Balixafortide TFA 还是一种有效的造血干细胞和祖细胞 (HSPC) 动员剂，并具有抗癌作用。
货号:ajcx16450
CAS:N/A
分子式:C82H113N22F3O23S2
分子量：1896.05
溶解度:Soluble in DMSO
纯度：98%
存储：Store at -20°C
库存：现货

Background:

Balixafortide TFA (POL6326 TFA) is a potent, selective, well-tolerated peptidic CXCR4 antagonist with an IC50< 10 nM. Balixafortide TFA shows 1000-fold selective for CXCR4 than a large panel of receptors including CXCR7. Balixafortide TFA blocks β-arrestin recruitment and calcium flux with IC50s< 10 nM. Balixafortide TFA is also a potent hematopoietic stem and progenitor cell (HSPC) mobilizing agent. Anti-cancer effects[1][2].

[1]. Zimmermann J, et al. Anti-tumor cell activity and in vitro profile of the next generation CXCR4 antagonist Balixafortide. Ann Oncol. 2018 Oct;29 Suppl 8:viii103. [2]. Karpova D, et al. Mobilization of hematopoietic stem cells with the novel CXCR4 antagonist POL6326 (balixafortide) in healthy volunteers-results of a dose escalation trial. J Transl Med. 2017 Jan 3;15(1):2.